Authors
Power, Rachel FHynes, Brian G
Moran, Darragh
Yagoub, Hatim
Kiernan, Gary
Ruggiero, Nicholas J
Kiernan, Thomas J
Affiliation
Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland.Issue Date
2012-10MeSH
AnimalsCoronary Artery Disease
Drug Design
Drug Therapy, Combination
Humans
Individualized Medicine
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Receptor, PAR-1
Receptors, Purinergic P2Y12
Metadata
Show full item recordCitation
Modern antiplatelet agents in coronary artery disease. 2012, 10 (10):1261-72 Expert Rev Cardiovasc TherJournal
Expert review of cardiovascular therapyDOI
10.1586/erc.12.127PubMed ID
23190065Abstract
Dual antiplatelet therapy is well recognized in the prevention of thrombotic complications of acute coronary syndrome and percutaneous coronary interventions. Despite clinical benefits of aspirin and clopidogrel therapy, a number of limitations curtail their efficacy: slow onset of action, variability in platelet inhibitory response and potential drug-drug interactions. Furthermore, the single platelet-activation pathway targeted by these agents allows continued platelet activation via other pathways, ensuring incomplete protection against ischemic events, thus, underscoring the need for alternate antiplatelet treatment strategies. A number of novel antiplatelet agents are currently in advance development and many have established superior effects on platelet inhibition, clinical outcomes and safety profile than clopidogrel in high-risk patients. The aim of this review is to provide an overview of the current status of P2Y12 receptor inhibition and PAR-1 antagonists in determining a future strategy for individualized antiplatelet therapy.Language
enISSN
1744-8344ae974a485f413a2113503eed53cd6c53
10.1586/erc.12.127